Yewan Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yewan Park has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Dong Hyun Sinn
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
7 shared publications - Geum-Youn Gwak
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
7 shared publications - Gi-Ae Kim
Department of Internal Medicine Kyung Hee University School of Medicine Seoul Korea
3 shared publications - Kyunga Kim
Biomedical Statistics Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Korea
3 shared publications - Jae-Jun Shim
Department of Internal Medicine, Kyung Hee University College of Medicine, Seoul, Korea
2 shared publications - Joo Hyun Oh
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
Mortality Risk in Steatotic Liver Disease Stratified by Cardiometabolic Risk Factors and Alcohol Consumption: A Nationwide Cohort Study
Yewan Park, Jooyi Jung, Seungbong Han, Hyeyeon Hong, Gi-Ae Kim. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl260003
- 15 October 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
Open AccessMortality Risk in Steatotic Liver Disease Stratified by Cardiometabolic Risk Factors and Alcohol Consumption: A Nationwide Cohort Study
Yewan Park, Jooyi Jung, Seungbong Han, Hyeyeon Hong, Gi-Ae Kim. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl260003
- Open Access
- 19 August 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
Short-Term Impact of Fine Particulate Matter on Hepatic Decompensation in Cirrhosis: A Nationwide Case-Crossover Study
Yewan Park, Suna Kang, Jihee Nam, Jin Lee, Hwamin Woo, Hyunsoo Kim, Sung-Won Kang, Juhee Cho, Danbee Kang, Geum-Youn Gwak. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl260039
- 19 August 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
Open AccessShort-Term Impact of Fine Particulate Matter on Hepatic Decompensation in Cirrhosis: A Nationwide Case-Crossover Study
Yewan Park, Suna Kang, Jihee Nam, Jin Lee, Hwamin Woo, Hyunsoo Kim, Sung-Won Kang, Juhee Cho, Danbee Kang, Geum-Youn Gwak. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl260039
- Open Access
- 31 March 2023
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 17 (4) , 620-628
Clinical Outcomes and Validation of Ursodeoxycholic Acid Response Scores in Patients with Korean Primary Biliary Cholangitis: A Multicenter Cohort Study
Jong-In Chang, Jung Hee Kim, Dong Hyun Sinn, Ju-Yeon Cho, Kwang Min Kim, Joo Hyun Oh, Yewan Park, Won Sohn, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, and Seung-Woon Paik. Gut and Liver 2023;17:620-8. https://doi.org/10.5009/gnl220420
- 31 March 2023
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 17 (4) , 620-628
Open AccessClinical Outcomes and Validation of Ursodeoxycholic Acid Response Scores in Patients with Korean Primary Biliary Cholangitis: A Multicenter Cohort Study
Jong-In Chang, Jung Hee Kim, Dong Hyun Sinn, Ju-Yeon Cho, Kwang Min Kim, Joo Hyun Oh, Yewan Park, Won Sohn, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, and Seung-Woon Paik. Gut and Liver 2023;17:620-8. https://doi.org/10.5009/gnl220420
- Open Access
- 23 March 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-8
Associations of physical activity domains and muscle strength exercise with non-alcoholic fatty liver disease: a nation-wide cohort study
It is unclear if various types and domains of exercise have an identical effect on non-alcoholic fatty liver disease (NAFLD). Thus, this study aimed to investigate associations of different physical activity domains and muscle strength exercise with NAFLD using a nation-wide cohort database. Adults aged 20–79 years who participated in the Korean National Health and Nutrition Examination Survey between 2014 and 2018 were analyzed. Hepatic steatosis index was used to identify NAFLD. Physical activity was assessed with the Global Physical Activity Questionnaire. Of 21,015 participants, 4942 (23.5%) had NAFLD. Participants with ≥ 150 min/week of total physical activity had a lower risk of NAFLD than those with < 150 min/week (the fully adjusted OR: 0.86, 95% CI 0.78–0.95). When the individual domain of physical activity was assessed, ≥ 150 min/week of recreation activity was associated with a reduced risk of NAFLD (OR: 0.77, 95% CI 0.67–0.88), whereas ≥ 150 min/week of travel or work activity was not. The fully adjusted OR for NAFLD comparing participants with ≥ 2/week to those with < 2/week of muscle strength exercise was 0.83 (95% CI 0.73–0.94). Muscle strength exercise ≥ 2/week showed a lower risk of NAFLD for all levels of total and each specific domains of physical activity except for ≥ 150 min/week of work activity. An increased level of physical activity and muscle strength exercise was associated with a reduced risk of NAFLD, albeit the effect varied depending on domains of physical activity. Thus, physical activity should be differentiated by domains for the management of NAFLD. Muscle strength exercise could also be a good option for individuals who could not perform moderate-to-vigorous physical activity.
- 23 March 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-8
Open AccessAssociations of physical activity domains and muscle strength exercise with non-alcoholic fatty liver disease: a nation-wide cohort study
It is unclear if various types and domains of exercise have an identical effect on non-alcoholic fatty liver disease (NAFLD). Thus, this study aimed to investigate associations of different physical activity domains and muscle strength exercise with NAFLD using a nation-wide cohort database. Adults aged 20–79 years who participated in the Korean National Health and Nutrition Examination Survey between 2014 and 2018 were analyzed. Hepatic steatosis index was used to identify NAFLD. Physical activity was assessed with the Global Physical Activity Questionnaire. Of 21,015 participants, 4942 (23.5%) had NAFLD. Participants with ≥ 150 min/week of total physical activity had a lower risk of NAFLD than those with < 150 min/week (the fully adjusted OR: 0.86, 95% CI 0.78–0.95). When the individual domain of physical activity was assessed, ≥ 150 min/week of recreation activity was associated with a reduced risk of NAFLD (OR: 0.77, 95% CI 0.67–0.88), whereas ≥ 150 min/week of travel or work activity was not. The fully adjusted OR for NAFLD comparing participants with ≥ 2/week to those with < 2/week of muscle strength exercise was 0.83 (95% CI 0.73–0.94). Muscle strength exercise ≥ 2/week showed a lower risk of NAFLD for all levels of total and each specific domains of physical activity except for ≥ 150 min/week of work activity. An increased level of physical activity and muscle strength exercise was associated with a reduced risk of NAFLD, albeit the effect varied depending on domains of physical activity. Thus, physical activity should be differentiated by domains for the management of NAFLD. Muscle strength exercise could also be a good option for individuals who could not perform moderate-to-vigorous physical activity.
- 23 February 2023
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 57 (6) , 739-740
Letter: comment on Park et al – the association of non‐alcoholic fatty liver disease between parents and adolescent children – authors' reply
- 23 February 2023
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 57 (6) , 739-740
Letter: comment on Park et al – the association of non‐alcoholic fatty liver disease between parents and adolescent children – authors' reply
- 23 December 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 57 (2) , 275-276
Letter: hereditary role in non‐alcoholic fatty liver disease – authors' reply
- 23 December 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 57 (2) , 275-276
Letter: hereditary role in non‐alcoholic fatty liver disease – authors' reply
- 21 October 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 57 (2) , 245-252
The association of non‐alcoholic fatty liver disease between parents and adolescent children
Background Data reporting the heritability of non-alcoholic fatty liver disease (NAFLD) are highly variable. Aims To investigate the association of NAFLD between parents and their adolescent children using a nationwide, population-based cohort. Methods We analysed 1737 families with both parents and adolescent children aged 12-18 who participated in Korean National Health and Nutrition Examination Surveys (KNHANES) between 2010 and 2019. NAFLD was defined by body mass index and elevated alanine aminotransferase levels in children and by the hepatic steatosis index in parents. Results The prevalence of NAFLD in adolescent children with either parent with NAFLD was higher than that in those without a parent with NAFLD (10.2% vs. 3.1%, p < 0.001). In a model fully adjusted for demographic, nutritional, behavioural and metabolic risk factors, children with either parent with NAFLD had a higher odds ratio (OR) for NAFLD (OR = 1.75, 95% CI: 1.02-3.00) than those without a parent with NAFLD. Compared to those without a parent with NAFLD, the fully adjusted ORs of NAFLD in children with paternal NAFLD, maternal NAFLD and NAFLD in both parents were 1.80 (95% CI: 1.01-3.20), 2.21 (95% CI: 1.11-4.42) and 2.60 (95% CI: 1.03-6.54), respectively. Conclusion Adolescent children with a parent with NAFLD were at increased risk of NAFLD; risk was higher when both parents had NAFLD. Further studies are needed to explore the benefit of NAFLD screening in children who have a parent with NAFLD.
- 21 October 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 57 (2) , 245-252
The association of non‐alcoholic fatty liver disease between parents and adolescent children
Background Data reporting the heritability of non-alcoholic fatty liver disease (NAFLD) are highly variable. Aims To investigate the association of NAFLD between parents and their adolescent children using a nationwide, population-based cohort. Methods We analysed 1737 families with both parents and adolescent children aged 12-18 who participated in Korean National Health and Nutrition Examination Surveys (KNHANES) between 2010 and 2019. NAFLD was defined by body mass index and elevated alanine aminotransferase levels in children and by the hepatic steatosis index in parents. Results The prevalence of NAFLD in adolescent children with either parent with NAFLD was higher than that in those without a parent with NAFLD (10.2% vs. 3.1%, p < 0.001). In a model fully adjusted for demographic, nutritional, behavioural and metabolic risk factors, children with either parent with NAFLD had a higher odds ratio (OR) for NAFLD (OR = 1.75, 95% CI: 1.02-3.00) than those without a parent with NAFLD. Compared to those without a parent with NAFLD, the fully adjusted ORs of NAFLD in children with paternal NAFLD, maternal NAFLD and NAFLD in both parents were 1.80 (95% CI: 1.01-3.20), 2.21 (95% CI: 1.11-4.42) and 2.60 (95% CI: 1.03-6.54), respectively. Conclusion Adolescent children with a parent with NAFLD were at increased risk of NAFLD; risk was higher when both parents had NAFLD. Further studies are needed to explore the benefit of NAFLD screening in children who have a parent with NAFLD.
- Open Access
- 17 August 2022
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (33) , e255
Incidence and Pattern of Aminotransferase Elevation During Anti-Hypertensive Therapy With Angiotensin-II Receptor Blockers
Choi WJ, et al. J Korean Med Sci. 2022 Aug;37(33):e255. https://doi.org/10.3346/jkms.2022.37.e255
- 17 August 2022
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (33) , e255
Open AccessIncidence and Pattern of Aminotransferase Elevation During Anti-Hypertensive Therapy With Angiotensin-II Receptor Blockers
Choi WJ, et al. J Korean Med Sci. 2022 Aug;37(33):e255. https://doi.org/10.3346/jkms.2022.37.e255
- 30 June 2021
- Published by Wolters Kluwer Health in Hepatology
- Vol. 74 (6) , 2988-2997
The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nation‐wide Cohort Study
Background and Aims: Breastfeeding has multiple effects on maternal health outcomes. However, the effect of breastfeeding on NAFLD in parous women remains unclear. Approach and Results: A total of 6,893 Korean parous women aged 30‐50 years who participated in the Korean National Health and Nutrition Examination Survey were assessed for the association between breastfeeding and NAFLD. Duration of lactation was calculated by dividing the total lactation period by the number of breastfed children. NAFLD was defined by the hepatic steatosis index. Of 6,893 women, 1,049 (15.2%) had NAFLD. Prevalence of NAFLD was 18.3%, 14.3%, 12.3%, 14.4%, and 15.8% in women with a breastfeeding period of <1, ≥1‐<3, ≥3‐<6, ≥6‐<12, and ≥12 months, respectively. In a fully adjusted model, breastfeeding (≥1 month) was associated with reduced NAFLD prevalence (OR, 0.67; 95% CI, 0.51‐0.89) after adjusting for metabolic, socioeconomic, and maternal risk factors. Fully adjusted ORs (95% CI) decreased with an increase of breastfeeding duration: 0.74 (0.49‐1.11), 0.70 (0.47‐1.05), 0.67 (0.48‐0.94), and 0.64 (0.46‐0.89) for women with ≥1‐<3, ≥3‐<6, ≥6‐<12, and ≥12 months of breastfeeding duration, respectively, compared to women with <1 month of breastfeeding duration. Such an association was also observed in all predefined subgroups without interaction. Conclusions: Breastfeeding showed a protective effect against NAFLD in later life of parous women, suggesting a maternal benefit of breastfeeding on NAFLD.
- 30 June 2021
- Published by Wolters Kluwer Health in Hepatology
- Vol. 74 (6) , 2988-2997
The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nation‐wide Cohort Study
Background and Aims: Breastfeeding has multiple effects on maternal health outcomes. However, the effect of breastfeeding on NAFLD in parous women remains unclear. Approach and Results: A total of 6,893 Korean parous women aged 30‐50 years who participated in the Korean National Health and Nutrition Examination Survey were assessed for the association between breastfeeding and NAFLD. Duration of lactation was calculated by dividing the total lactation period by the number of breastfed children. NAFLD was defined by the hepatic steatosis index. Of 6,893 women, 1,049 (15.2%) had NAFLD. Prevalence of NAFLD was 18.3%, 14.3%, 12.3%, 14.4%, and 15.8% in women with a breastfeeding period of <1, ≥1‐<3, ≥3‐<6, ≥6‐<12, and ≥12 months, respectively. In a fully adjusted model, breastfeeding (≥1 month) was associated with reduced NAFLD prevalence (OR, 0.67; 95% CI, 0.51‐0.89) after adjusting for metabolic, socioeconomic, and maternal risk factors. Fully adjusted ORs (95% CI) decreased with an increase of breastfeeding duration: 0.74 (0.49‐1.11), 0.70 (0.47‐1.05), 0.67 (0.48‐0.94), and 0.64 (0.46‐0.89) for women with ≥1‐<3, ≥3‐<6, ≥6‐<12, and ≥12 months of breastfeeding duration, respectively, compared to women with <1 month of breastfeeding duration. Such an association was also observed in all predefined subgroups without interaction. Conclusions: Breastfeeding showed a protective effect against NAFLD in later life of parous women, suggesting a maternal benefit of breastfeeding on NAFLD.
Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study
Objective Direct comparison of the clinical outcomes between nucleos(t)ide analogue (NA) discontinuation versus NA continuation has not been performed in patients with chronic hepatitis B who achieved HBsAg-seroclearance. Whether NA discontinuation was as safe as NA continuation after NA-induced surface antigen of HBV (HBsAg) seroclearance was investigated in the present study. Designs This multicentre study included 276 patients from 16 hospitals in Korea who achieved NA-induced HBsAg seroclearance: 131 (47.5%) discontinued NA treatment within 6 months after HBsAg seroclearance (NA discontinuation group) and 145 (52.5%) continued NA treatment (NA continuation group). Primary endpoint was HBsAg reversion and secondary endpoints included serum HBV DNA redetection and development of hepatocellular carcinoma (HCC). Results During follow-up (median=26.9 months, IQR=12.2–49.2 months), 10 patients (3.6%) experienced HBsAg reversion, 6 (2.2%) showed HBV DNA redetection and 8 (2.9%) developed HCC. Compared with NA continuation, NA discontinuation was not associated with HBsAg reversion in both univariable (HR=0.45, 95% CI=0.12 to 1.76, log-rank p=0.24) and multivariable analyses (adjusted HR=0.65, 95% CI=0.16 to 2.59, p=0.54). The cumulative probabilities of HBsAg reversion at 1, 3 and 5 years were 0.8%, 2.3% and 5.0% in the NA discontinuation group, and 1.5%, 6.3% and 8.4% in the NA continuation group, respectively. NA discontinuation was not associated with higher risk of either HBV redetection (HR=0.83, 95% CI=0.16 to 4.16, log-rank p=0.82) or HCC development (HR=0.53, 95% CI=0.12 to 2.23, log-rank p=0.38). Conclusion The discontinuation of NA was not associated with a higher risk of either HBsAg reversion, serum HBV DNA redetection or HCC development compared with NA continuation among patients who achieved HBsAg seroclearance with NA.
Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study
Objective Direct comparison of the clinical outcomes between nucleos(t)ide analogue (NA) discontinuation versus NA continuation has not been performed in patients with chronic hepatitis B who achieved HBsAg-seroclearance. Whether NA discontinuation was as safe as NA continuation after NA-induced surface antigen of HBV (HBsAg) seroclearance was investigated in the present study. Designs This multicentre study included 276 patients from 16 hospitals in Korea who achieved NA-induced HBsAg seroclearance: 131 (47.5%) discontinued NA treatment within 6 months after HBsAg seroclearance (NA discontinuation group) and 145 (52.5%) continued NA treatment (NA continuation group). Primary endpoint was HBsAg reversion and secondary endpoints included serum HBV DNA redetection and development of hepatocellular carcinoma (HCC). Results During follow-up (median=26.9 months, IQR=12.2–49.2 months), 10 patients (3.6%) experienced HBsAg reversion, 6 (2.2%) showed HBV DNA redetection and 8 (2.9%) developed HCC. Compared with NA continuation, NA discontinuation was not associated with HBsAg reversion in both univariable (HR=0.45, 95% CI=0.12 to 1.76, log-rank p=0.24) and multivariable analyses (adjusted HR=0.65, 95% CI=0.16 to 2.59, p=0.54). The cumulative probabilities of HBsAg reversion at 1, 3 and 5 years were 0.8%, 2.3% and 5.0% in the NA discontinuation group, and 1.5%, 6.3% and 8.4% in the NA continuation group, respectively. NA discontinuation was not associated with higher risk of either HBV redetection (HR=0.83, 95% CI=0.16 to 4.16, log-rank p=0.82) or HCC development (HR=0.53, 95% CI=0.12 to 2.23, log-rank p=0.38). Conclusion The discontinuation of NA was not associated with a higher risk of either HBsAg reversion, serum HBV DNA redetection or HCC development compared with NA continuation among patients who achieved HBsAg seroclearance with NA.